Angioplasty, a surgical procedure that opens blocked arteries, often involves placing a metal tube to hold arterial walls open and prevent them from collapsing once the arterial block is surgically removed. However, a bare metal stent (BMS) causes some injury to the walls of the blood vessel walls, which triggers smooth muscle cells to multiply and migrate to the site to repair the injury
By Pat Anson, PNN Editor A California stem cell company has announced positive results from a small, early-stage clinical trial of an experimental stem cell therapy for knee osteoarthritis. The Phase 1/2a trial conducted by Personalized Stem Cells (PSC) involved 39 patients with knee osteoarthritis who were given a single injection of autologous mesenchymal stem cells derived from their own body fat. Safety was the primary objective of the trial and there were no serious adverse events reported by the company
Making accurate business decisions is always a tough task. However, if the company has acquired proper insights about the market, making those decisions becomes easy. DataIntelo offers the right support any business requires in the form of its meticulous research reports
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. MELVILLE, N.Y., March 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Gosselies, Belgium, 30March 2021, 7am CEST BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces the appointment of the stem cell therapy industry veteran, Anthony Ting, PhD, as Chief Scientific Officer (CSO)
Institute has backing of executives culled from FIRST founders well-worn and overflowing RolodexCaARMI | BioFabUSA CTO Tom Bollenbach consults with Dr. Mary Clare McCorry, director of technology and process development at the ARMI institute. Good science does not equate to workable manufacturing
As many as 40% of COVID-19 patients in intensive care never recover, but some experts say there may be hope for these severely ill victims in the discarded byproduct of birth. According to the National Post, umbilical cord cells offer promise for gravely ill COVID-19 patients. Canadian researchers and other scientists believe that the mesenchymal stem cells that are richly abundant in umbilical cords could help restore damaged immune systems
This article was originally published here Front Cell Dev Biol. 2021 Mar 8;8:596170. doi: 10.3389/fcell.2020.596170
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento")announcedtodayupdated positiveresultsfrom itsPhase 1bstudy ofhumanallogeneicadipose-derivedmesenchymal stemcells(COVI-MSC)forpatients suffering from COVID-19-induced acute respiratory distress (ARD)oracute respiratory distress syndrome (ARDS). Thisongoingstudy (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy ofCOVI-MSCsadministered every other day for three infusions for a total of 1 x 106cells/kg
https://www.lexisbusinessinsights.com/Global Human Mesenchymal Stem Cells (hMSC) Market Status and Forecast (2021-2027) by Region, Product Type & End-UseThe Lexis Business Insights added a new report Global Human Mesenchymal Stem Cells (hMSC) Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015 2027 in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting. In 2020, the global Human Mesenchymal Stem Cells (hMSC) Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2027, with a CAGR of xx% during 2020-2027
Recent Comments